Path Diagnostic Therapeutic Care (PDTA) in children and adolescents with headache

Raieli, Vincenzo; Vecchio, A; Consolo, Flavia; Santangelo, Giuseppe; Pitino, Renata; Porrello, Giuseppe; Vanadia, Francesca

doi:10.1186/1824-7288-40-s1-a85

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is an urgent need for a shared clinical and scientific management strategy that will shed light on neglected areas of clinical governance in relation to CM, minimise the risk of misdiagnosis, rationalise healthcare resource allocation and ensure that patients receive the treatment that best suits their clinical and personal needs. For example, establishing diagnostic and care plans, similar to the one implemented in Palermo for the management of pediatric headache [84], would provide a clear pathway through the diagnostic process, and would help to eliminate redundancy and unnecessary diagnostic procedures or treatments and channel appropriate patients to specialised care in multidisciplinary headache centers. These centers are best placed to identify patients with CM or EM that is trending towards chronicity, and particularly to make a differential diagnosis in patients with other conditions that can mimic CM.…”

Section: Chronic Migraine Management In Italymentioning

confidence: 99%

Current and emerging evidence-based treatment options in chronic migraine: a narrative review

et al. 2019

View full text Add to dashboard Cite

BackgroundChronic migraine is a disabling condition that is currently underdiagnosed and undertreated. In this narrative review, we discuss the future of chronic migraine management in relation to recent progress in evidence-based pharmacological treatment.FindingsPatients with chronic migraine require prophylactic therapy to reduce the frequency of migraine attacks, but the only currently available evidence-based prophylactic treatment options for chronic migraine are topiramate and onabotulinumtoxinA. Improved prophylactic therapy is needed to reduce the high burden of chronic migraine in Italy. Monoclonal antibodies that target the calcitonin gene-related peptide (CGRP) pathway of migraine pathogenesis have been specifically developed for the prophylactic treatment of chronic migraine. These anti-CGRP/R monoclonal antibodies have demonstrated good efficacy and excellent tolerability in phase II and III clinical trials, and offer new hope to patients who are currently not taking any prophylactic therapy or not benefitting from their current treatment.ConclusionsTreatment of chronic migraine is a dynamic and rapidly advancing area of research. New developments in this field have the potential to improve the diagnosis and provide more individualised treatments for this condition. Establishing a culture of prevention is essential for reducing the personal, social and economic burden of chronic migraine.

show abstract

Section: Chronic Migraine Management In Italymentioning

confidence: 99%